Compare SOTK & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOTK | UNCY |
|---|---|---|
| Founded | 1975 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8M | 145.3M |
| IPO Year | 1995 | 2021 |
| Metric | SOTK | UNCY |
|---|---|---|
| Price | $4.38 | $7.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $25.67 |
| AVG Volume (30 Days) | 17.9K | ★ 554.7K |
| Earning Date | 05-27-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $20,504,381.00 | $675,000.00 |
| Revenue This Year | $4.02 | N/A |
| Revenue Next Year | $10.95 | $582.86 |
| P/E Ratio | $53.88 | ★ N/A |
| Revenue Growth | ★ 4.08 | N/A |
| 52 Week Low | $3.23 | $0.47 |
| 52 Week High | $5.15 | $7.78 |
| Indicator | SOTK | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 65.27 | 57.44 |
| Support Level | $4.36 | $5.95 |
| Resistance Level | $4.45 | N/A |
| Average True Range (ATR) | 0.17 | 0.40 |
| MACD | 0.04 | 0.09 |
| Stochastic Oscillator | 96.55 | 72.04 |
Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.